Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:22 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes

NCT05035368 · Dompé Farmaceutici S.p.A · PHASE2 · withdrawn · last registry update 2023-12-22 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Kind	Quote	Our category	Source
Stated	“Dompé decided to withdraw LDX0121 following an internal re-planning and an extensive review of the study design. At the time of withdrawal, no site had been activated and the drug had not been sent to investigators. No patients had been enrolled.”	–	Registry record, Dompé Farmaceutici S.p.A

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against CXCR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

Internal portfolio and board discussions
Unpublished trial data and interim analyses
Terms of any partner or licence decision